Literature DB >> 8407229

Nonocular Chlamydia infection and risk of ocular reinfection after mass treatment in a trachoma hyperendemic area.

S West1, B Muñoz, L Bobo, T C Quinn, H Mkocha, M Lynch, B B Mmbaga, R Viscidi.   

Abstract

PURPOSE: The presence of nasal discharge on a child's face increases the risk of active trachoma, suggesting that Chlamydia trachomatis in nasal secretions may be a possible source of ocular reinfection. The prevalence of chlamydia in nasal secretions and the risk of reinfection after mass treatment was investigated in a hyperendemic area of Tanzania.
METHODS: In one village a total of 232 children aged 1 to 7 years were followed before and after mass treatment. Clinical trachoma, and microbiologic evidence of chlamydia, were assessed at baseline, 2 and 4 weeks into mass treatment, and 4 weeks after treatment stopped. The presence of chlamydia in ocular and nasal secretions was determined by polymerase chain reaction-enzyme immunoassay techniques.
RESULTS: Of the 232 children, 59% had clinical trachoma and 27% had nasal specimens positive for chlamydia. Children with positive ocular chlamydia specimens and/or clinical trachoma were significantly more likely to have positive nasal specimens. At the end of mass treatment, only 4% of children had positive ocular specimens. However, 1 month after treatment stopped, the incidence of new infection was 21%. The rate of new ocular infections in those who had negative ocular specimens after treatment was similar between those who had positive and those who had negative nasal specimens at baseline. Positive ocular specimens at baseline was not a predictor of risk of new infection after treatment (odds ratio = 1.18, 95% confidence interval = 0.58, 2.40), suggesting these new infections were not the result of latent or persistent organism.
CONCLUSIONS: These data do not support a role for nasal secretions in causing reinfection after treatment. One mass topical treatment alone is unlikely to be effective in trachoma hyperendemic areas as shown by the rapid re-emergence of infection.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8407229

Source DB:  PubMed          Journal:  Invest Ophthalmol Vis Sci        ISSN: 0146-0404            Impact factor:   4.799


  13 in total

1.  Can we eliminate trachoma?

Authors:  T Lietman; A Fry
Journal:  Br J Ophthalmol       Date:  2001-04       Impact factor: 4.638

2.  Impact of oral azithromycin on recurrence of trachomatous trichiasis in Nepal over 1 year.

Authors:  H Zhang; R P Kandel; H K Atakari; D Dean
Journal:  Br J Ophthalmol       Date:  2006-05-10       Impact factor: 4.638

3.  A Longitudinal Analysis of Chlamydial Infection and Trachomatous Inflammation Following Mass Azithromycin Distribution.

Authors:  Daniel P Morberg; Wondu Alemayehu; Muluken Melese; Takele Lakew; Alemayehu Sisay; Zhaoxia Zhou; Vicky Cevallos; Catherine E Oldenburg; Travis C Porco; Thomas M Lietman; Jeremy D Keenan
Journal:  Ophthalmic Epidemiol       Date:  2018-08-28       Impact factor: 1.648

Review 4.  Trachoma.

Authors:  Anthony W Solomon; Matthew J Burton; Emily W Gower; Emma M Harding-Esch; Catherine E Oldenburg; Hugh R Taylor; Lamine Traoré
Journal:  Nat Rev Dis Primers       Date:  2022-05-26       Impact factor: 52.329

Review 5.  Diagnosis and assessment of trachoma.

Authors:  Anthony W Solomon; Rosanna W Peeling; Allen Foster; David C W Mabey
Journal:  Clin Microbiol Rev       Date:  2004-10       Impact factor: 26.132

Review 6.  Chlamydia trachomatis today: treatment, detection, immunogenetics and the need for a greater global understanding of chlamydial disease pathogenesis.

Authors:  D Dean
Journal:  Drugs Today (Barc)       Date:  2009-11       Impact factor: 2.245

7.  The relationship between prevalence of active trachoma, water availability and its use in a Tanzanian village.

Authors:  Sarah Polack; Hannah Kuper; Anthony W Solomon; Patrick A Massae; Carolina Abuelo; Ewen Cameron; Vivian Valdmanis; Michael Mahande; Allen Foster; David Mabey
Journal:  Trans R Soc Trop Med Hyg       Date:  2006-03-20       Impact factor: 2.184

8.  Chlamydial positivity of nasal discharge at baseline is associated with ocular chlamydial positivity 2 months following azithromycin treatment.

Authors:  Emily West Gower; Anthony W Solomon; Matthew J Burton; Aura Aguirre; Beatriz Muñoz; Robin Bailey; Martin Holland; Pateh Makalo; Patrick Massae; Harran Mkocha; David C Mabey; Sheila K West
Journal:  Invest Ophthalmol Vis Sci       Date:  2006-11       Impact factor: 4.799

9.  Chlamydia trachomatis ompA variants in trachoma: what do they tell us?

Authors:  Aura A Andreasen; Matthew J Burton; Martin J Holland; Spencer Polley; Nkoyo Faal; David C W Mabey; Robin L Bailey
Journal:  PLoS Negl Trop Dis       Date:  2008-09-24

10.  Multiple Chlamydiaceae species in trachoma: implications for disease pathogenesis and control.

Authors:  Deborah Dean; Ram P Kandel; Him K Adhikari; Tracey Hessel
Journal:  PLoS Med       Date:  2008-01-03       Impact factor: 11.069

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.